Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Oncologist · 2018 · PMC5947454 · PMID 29472310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There was a trend for increased PFS and OS in patients with methylated promoter O‐6‐methylguanine‐DNA methyltransferase (MGMT) status; however, in contrast to our previous study that used TMZ alone, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.